January 17, 2017
Novo Nordisk sails into “Safe Harbour”, repurchases shares
Novo Nordisk has initiated a share repurchase programme in accordance with certain European regulations known as the Safe Harbour rules.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
January 16, 2017
MML enters into new supply agreement with Uruguay’s CCC
Mainstay Medical International’s subsidiary Mainstay Medical Limited (MML) has made a new supply deal with Centro de Construccion de Cardioestimuladores del Uruguay S.A. (CCC)
January 16, 2017
Cresco Pharma requests trading halt
Creso Pharma Limited, the company that Creso Pharma, the company focused on cannabis derived therapeutics, requests that its securities to be placed in a trading halt.
January 16, 2017
FIT Biotech Oy’s converts convertible notes into shares
Related to Convertible Note and Warrant Programmes established on September 26, 2016 between the Fit Biotech Oy and Bracknor Investment,…
January 16, 2017
Chi-Med kicks off two cancer drug studies in China
AIM and Nasdaq listed pharmaceutical company, Hutchison China MediTech Limited (Chi-Med) has initiated two Phase II studies in China for testing cancer treatments.
January 16, 2017
University of Michigan Pancreatic Cancer Center, Immunovia partner up in fighting pancreatic cancer
University of Michigan Pancreatic Cancer Center has become the most recent member of the global network of prominent sites participating…
January 16, 2017
Safe Orthopaedics to sell bone substitute for its Walnut cage for cervical surgeries in Europe
Safe Orthopaedics has started selling a bone substitute for its Walnut cage for cervical surgeries in Europe.
January 16, 2017
Horizon Discovery broadens gene editing capabilities through extension of key CRISPR license and grant-funded research
Horizon Discovery has broadened its gene editing capabilities through the amendment of a pre-existing license with ERS Genomics to include…
January 13, 2017
Pharma company executives debate drug pricing increases
The pharmaceutical industry is typically reluctant to talk about U.S. drug prices, generally the highest in the world due to a combination of market fragmentation and free market policies. But recent high-profile price hikes by Mylan NV, Turing Pharmaceuticals and Valeant Pharmaceuticals International have raised the ire of consumers and lawmakers.
January 13, 2017
Eli Lilly v. Teva Parenteral Medicines over vitamin regimen patent for Alimta
U.S. Court of Appeals for the Federal Circuit has upheld the district court’s decision and ruled in the Eli Lilly’s favor regarding validity and infringement of the vitamin regimen patent for Alimta (pemetrexed for injection).